PetMETA is a Nuclear Magnetic Resonance spectroscopy (NMR) metabolomics testing panel calibrated for canine use. NMR is the most suitable metabolomics technology for clinical use, since it requires a small sample volume and offers quantitative data with high reproducibility, high throughput and excellent scalability in a non-destructive and cost-effective way. Multiple sample materials can be used for the analysis: heparin plasma, serum or EDTA plasma.

 

Cutting-edge technology

Nuclear Magnetic Resonance spectroscopy (NMR) is based on the interaction of atomic nuclei with a magnetic field. Molecules generate distinct peaks in the NMR spectrum based on their chemical structure. The intensity of the molecules’ NMR signal is directly proportional to the number of nuclei of that molecule. Thus, as the molecular concentration increases, a linear increase in the NMR signal intensity is observed. Molecular concentrations are calculated from the intensities of these signals. Some of the biomarkers in the test are measured from the intensity of the individual peak created by that specific molecule, while others are measured from a larger signal cluster using a canine-specific computational model. No reagents are needed for NMR analysis, the device is not in direct contact with the sample material, and the radio frequency radiation absorbed by the sample does not damage the sample. Thus, the method is robust against lot-to-lot variation.

 

Canine-specific analysis

The analysis is based on information about the molecules’ chemical structure and the individual signals they produce. The analysis has been developed using both spiking studies (studying the signal from a purified molecule), and comparing results with reference testing methods. The small molecules included in the test are measured directly from their characteristic signals. In turn, the lipid panel is based on a dog-specific algorithm calibrated against external reference laboratories’ results.

 

Wide coverage

The NMR testing panel is capable of quantifying over 120 biomarkers. These biomarkers include both well-known analytes as well as previously unmeasured biomarkers. The biomarkers included in the  clinical PetMETA -test have been selected from these biomarkers based on their estimated biological significance, prior research, and stability in typical clinical chemistry sample shipping conditions. The entire test content, including research phase biomarkers, can be provided on request.